Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -26.24% is 21% above its 5-year average of -33.24%, around the middle of its 5-year range (-54.65%–-3.73%).
117.13% below its 12-month average of -12.09%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.08%.
RETURN ON ASSETS (ROA)
-26.24%
RETURN ON ASSETS (ROA) AVG TTM
-12.09%
RETURN ON ASSETS (ROA) AVG 3Y
-27.60%
RETURN ON ASSETS (ROA) AVG 5Y
-33.24%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-117.13%
CURRENT VS 3Y AVG
+4.94%
CURRENT VS 5Y AVG
+21.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.01%
median of 644 covered companies
CURRENT VS SECTOR MEDIAN
+9.53%
vs the sector median at left
Fulcrum Therapeutics, Inc.
Market Cap
$283.44M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$286.16M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$278.62M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$291.83M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$280.84M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$276.83M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$292.34M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$292.79M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$266.79M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $283.44M | -26.24% | -12.09% | -27.60% | -33.24% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.16M | -35.03% | -13.04% | -43.14% | -55.84% |
| Aurora Cannabis Inc. (ACB)vs › | $278.62M | -18.18% | -10.00% | -29.10% | -54.94% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.83M | -104.42% | -76.93% | -55.08% | -54.19% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $280.84M | -128.66% | -214.31% | -145.75% | -133.94% |
| Fate Therapeutics, Inc. (FATE)vs › | $276.83M | -48.44% | -42.51% | -39.18% | -34.60% |
| Standard BioTools Inc. (LAB)vs › | $292.34M | -13.93% | -17.93% | -26.92% | -24.25% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $292.79M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.79M | -134.38% | -47.50% | -42.91% | -40.55% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.17M | -35.96% | -58.88% | -82.10% | -113.46% |
ROA
-26.2%
ROE
-27.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -20.44% |
| 2024-12-31 | -3.73% |
| 2023-12-31 | -37.77% |
| 2022-12-31 | -48.47% |
| 2021-12-31 | -34.40% |
| 2020-12-31 | -54.65% |
| 2019-12-31 | -74.86% |
| 2018-12-31 | -37.99% |
| 2017-12-31 | -529.12% |
